ADAMIS PHARMACEUTICALS CORPORATION

(ADMP)
  Report
Delayed Nasdaq  -  04:00 2022-08-10 pm EDT
0.3710 USD   +0.19%
08/10ADAMIS : Q2 Earnings Snapshot
AQ
08/10ADAMIS PHARMACEUTICALS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MANAGEMENT TO HOST WEBCAST/CONFERENCE CALL TODAY AT : 30 p.m. PT / 4:30 p.m. ET - Form 8-K
PU
08/10ADAMIS PHARMACEUTICALS CORP Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company. The Company is focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory diseases. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg, which is used in the emergency treatment of acute allergic reactions, including anaphylaxis, for patients weighing 66 pounds or more; and SYMJEPI (epinephrine) Injection 0.15mg, which is used in the treatment of anaphylaxis for patients weighing 33-65 pounds. Its other product candidates include ZIMHI (naloxone) Injection, which is used for the treatment of opioid overdose; and Tempol (APC-400), an investigational drug, which is used in the fields of COVID-19 infection, asthma, respiratory syncytial virus infection, and influenza infection. It also has a microbicide product candidate, named C31G.

Number of employees : 15 people.
Sales per Business
2021
Drug Development and Commercialization2.21100%
USD in Million
Sales per region
20202021Delta
United States16.53100%2.21100% -86.64%
USD in Million
Managers
Name Title Age Since
David J. Marguglio Director & Vice President-Business Development 50 2006
David C. Benedicto Chief Financial & Accounting Officer 61 2021
Ronald B. Moss, Dr. Chief Medical Officer 61 2017
Thomas H. Moll, Dr. Vice President-Research 55 2009
Members of the board
Name Title Age Since
Richard C. Williams Chairman 77 2014
Howard C. Birndorf, Dr. Independent Director 71 2019
Meera J. Desai, Dr. Independent Director 43 2021
Vickie Reed Independent Director 59 2022
David J. Marguglio Director & Vice President-Business Development 50 2006
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 150,506,222 148,379,339 98.6% 522,957 0.3% 98.6%
Shareholders
NameEquities%
The Vanguard Group, Inc. 6,423,273 4.29%
Heights Capital Management, Inc. 3,397,916 2.27%
Anson Funds Management LP 3,013,054 2.01%
BlackRock Fund Advisors 2,727,943 1.82%
683 Capital Management LLC 1,938,825 1.29%
Sio Capital Management LLC 1,935,961 1.29%
Balyasny Asset Management LP 1,622,510 1.08%
First Manhattan Co. 1,391,733 0.93%
Geode Capital Management LLC 1,293,316 0.86%
Deka Investment GmbH 1,200,000 0.80%
Company contact information
Adamis Pharmaceuticals Corp.
11682 El Camino Real
Suite 300
San Diego, CA 92130

Phone : +1.858.997.2400
Web : http://www.adamispharmaceuticals.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Adamis Pharmaceuticals Corporation
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
ADAMIS PHARMACEUTICALS CORPORATION-38.68%56
JOHNSON & JOHNSON-0.23%448 722
ELI LILLY AND COMPANY9.70%289 433
PFIZER, INC.-15.70%280 264
ROCHE HOLDING AG-16.02%278 152
ABBVIE INC.3.58%249 196
NOVO NORDISK A/S4.27%246 516
MERCK & CO., INC.16.38%225 943
ASTRAZENECA PLC24.66%205 444
NOVARTIS AG3.71%191 465
BRISTOL-MYERS SQUIBB COMPANY20.22%159 845
AMGEN INC.12.05%134 851
SANOFI-1.03%113 615
GSK PLC-5.29%77 234
BAYER AG10.43%52 777
DAIICHI SANKYO CO., LTD.23.11%52 567
CHUGAI PHARMACEUTICAL CO., LTD1.29%47 000
TAKEDA PHARMACEUTICAL COMPANY LIMITED19.48%44 151
JIANGSU HENGRUI MEDICINE CO., LTD.-27.33%34 961
ASTELLAS PHARMA INC.9.25%27 791
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD-32.97%26 295
Connections : Adamis Pharmaceuticals Corporation